GlassScriptPhysician profile
Jean Robert Macenat
NPI 1104886860
$11,982.35
in general payments reported to CMS, 2019-2025
39 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,775 · 2020: $1,753 · 2021: $1,859 · 2022: $1,580 · 2023: $1,502 · 2024: $1,232 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,015.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,842.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,314.95 | 2019-2025 | Farxiga |
| Allergan, INC. | $1,045.75 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $702.59 | 2019-2025 | Verquvo, Steglatro, Capvaxive |
| Amgen INC. | $639.36 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $595.68 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $519.79 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $488.15 | 2019-2021 | |
| Horizon Therapeutics Plc | $450.16 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $439.21 | 2019-2024 | Mounjaro, Lyumjev, Jardiance |
| Novo Nordisk INC | $418.61 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $391.52 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $371.40 | 2020-2023 | |
| Glaxosmithkline, LLC. | $331.41 | 2019-2023 | Shingrix, Arexvy |
| Mannkind Corporation | $264.92 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Macenat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.